Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicadrostat plus empagliflozin in heart failure with reduced ejection fraction
NL-OMON60057Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in heart failure (HF) and heart failure with reduced ejection fraction (HFrEF) comparing Vicadrostat + empagliflozin with Placebo + empagliflozin (2 arms). Primary endpoint: Primary composite endpoint. Started Nov 2025; status: recruiting.
02
Drugs
vicadrostatempagliflozin
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON60057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60057.